Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Clovis Oncology, Inc.CLVS · Entity 122635 | Director · See Remarks | March 01, 2022 | March 03, 2022 |
| Medicus Pharma Ltd.MDCX · Entity 7770 | Director | June 03, 2026 | June 04, 2026 |
| Orexigen Therapeutics, Inc.OREX · Entity 157016 | Director | July 14, 2017 | July 18, 2017 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Clovis Oncology, Inc.
Report date March 01, 2022 · Filed March 03, 2022
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $1.95 · Expires 2032-03-01 | Direct | 220,000 |
Reported balance
After 2022-03-01 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2022-03-01 · Grant · Acquired 220,000 · Balance 220,000 F1: The option shall vest as to 25% of the shares on March 1, 2023, and the remainder shall vest in substantially equal installments over the 36 months immediately following such date. |
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $1.95 · Expires 2032-03-01 | Direct | 80,000 |
Reported balance
After 2022-03-01 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2022-03-01 · Grant · Acquired 80,000 · Balance 80,000 F2: The option shall vest in the event Product Revenues for the Company's fiscal year ending December 31, 2022 meet or exceed its corresponding budgeted amount in the Company's budget as approved by the Board on December 2, 2021. |
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $1.95 · Expires 2032-03-01 | Direct | 80,000 |
Reported balance
After 2022-03-01 transaction · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · 2022-03-01 · Grant · Acquired 80,000 · Balance 80,000 F3: The option shall vest on December 31, 2022 if as of such date the Company has sufficient cash and cash equivalents or available sources of borrowings to fund the Company's operating plan, as approved by the Board as of such date, into 2024. |
Filing footnotes · ownership attribution and instrument terms
F1: The option shall vest as to 25% of the shares on March 1, 2023, and the remainder shall vest in substantially equal installments over the 36 months immediately following such date.
F2: The option shall vest in the event Product Revenues for the Company's fiscal year ending December 31, 2022 meet or exceed its corresponding budgeted amount in the Company's budget as approved by the Board on December 2, 2021.
F3: The option shall vest on December 31, 2022 if as of such date the Company has sufficient cash and cash equivalents or available sources of borrowings to fund the Company's operating plan, as approved by the Board as of such date, into 2024.
Medicus Pharma Ltd.
Report date June 03, 2026 · Filed June 04, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $0.36 · Expires 2031-06-03 | Direct | 50,000 |
Reported balance
After 2026-06-03 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2026-06-03 · Grant · Acquired 50,000 · Balance 50,000 F1: The option was granted on June 3, 2026. The option is scheduled to vest quarterly in four equal installments over one year. |
Filing footnotes · ownership attribution and instrument terms
F1: The option was granted on June 3, 2026. The option is scheduled to vest quarterly in four equal installments over one year.
Orexigen Therapeutics, Inc.
Report date July 14, 2017 · Filed July 18, 2017
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $2.88 · Expires 2027-07-13 | Direct | 5,000 |
Reported balance
After 2017-07-14 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2017-07-14 · Grant · Acquired 5,000 · Balance 5,000 F1: 1/12th of the original number of shares of stock subject to the option (rounded down to the next whole number of shares) shall vest in equal monthly installments over 12 months following the vesting commencement date of July 14, 2017, subject to the Reporting Person's continuing service on the Issuer's Board of Directors through each such date, and subject to the terms of the Stock Option Agreement in the event of a change in control of the Issuer. |
Filing footnotes · ownership attribution and instrument terms
F1: 1/12th of the original number of shares of stock subject to the option (rounded down to the next whole number of shares) shall vest in equal monthly installments over 12 months following the vesting commencement date of July 14, 2017, subject to the Reporting Person's continuing service on the Issuer's Board of Directors through each such date, and subject to the terms of the Stock Option Agreement in the event of a change in control of the Issuer.
Past disclosures · reporting ended (1)
No longer tracked through insider filings. These historical balances do not imply present ownership or a zero position.
Flexion Therapeutics Inc
Report date November 19, 2021 · Filed November 19, 2021
Section 16 reporting ended · disclosed 2021-11-19. Current position is not established by this disclosure.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 0 |
Reported balance
After 2021-11-19 transaction · row 1
1 source rowRow 1 · 2021-11-19 · Disposition to issuer · Disposed 39,824 · Balance 0 F1: Pursuant to the Agreement and Plan of Merger, dated as of October 11, 2021, by and among Flexion Therapeutics, Inc. ("Issuer"), Pacira BioSciences, Inc. and Oyster Acquisition Company Inc. ("Purchaser") ("Merger Agreement"), on November 19, 2021, Purchaser merged with and into Issuer, with Issuer continuing as the surviving corporation ("Merger"). At the effective time of the Merger, each share of Issuer's common stock was cancelled in exchange for (i) $8.50 per share in cash ("Cash Amount"), plus (ii) one non-transferable contractual contingent value right per share, which represent the right to receive one or more contingent payments of up to $8.00 per share in the aggregate, in cash, upon the achievement of specified milestones on or prior to December 31, 2030 ("CVR Payments"). Pursuant to the Merger Agreement, these shares were tendered and disposed of at the offer acceptance time in exchange for the right to receive (i) the Cash Amount, plus (ii) any CVR Payments. F2: At the effective time of the Merger, each outstanding restricted stock unit award ("RSU") was accelerated and became fully vested and was cancelled and converted into the right to receive (i) $8.50 per share of Issuer common stock issuable in settlement of such RSU in cash, net of any withholding taxes required to be deducted and withheld by applicable law, plus (ii) any potential CVR Payments. |
| Stock option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $17.61 · Expires 2024-03-02 | Direct | 0 |
Reported balance
After 2021-11-19 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2021-11-19 · Disposition to issuer · Disposed 18,000 · Balance 0 F3: At the effective time of the Merger, each outstanding option with an exercise price equal to, or greater than, $9.12 was cancelled without any consideration payable (whether in the form of cash or any potential CVR Payments) in respect of such cancelled option. |
| Stock option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $21.85 · Expires 2025-06-16 | Direct | 0 |
Reported balance
After 2021-11-19 transaction · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · 2021-11-19 · Disposition to issuer · Disposed 18,000 · Balance 0 F3: At the effective time of the Merger, each outstanding option with an exercise price equal to, or greater than, $9.12 was cancelled without any consideration payable (whether in the form of cash or any potential CVR Payments) in respect of such cancelled option. |
| Stock option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $13.83 · Expires 2026-06-09 | Direct | 0 |
Reported balance
After 2021-11-19 transaction · row 4
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 4 · 2021-11-19 · Disposition to issuer · Disposed 18,000 · Balance 0 F3: At the effective time of the Merger, each outstanding option with an exercise price equal to, or greater than, $9.12 was cancelled without any consideration payable (whether in the form of cash or any potential CVR Payments) in respect of such cancelled option. |
| Stock option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $20.16 · Expires 2027-06-21 | Direct | 0 |
Reported balance
After 2021-11-19 transaction · row 5
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 5 · 2021-11-19 · Disposition to issuer · Disposed 18,000 · Balance 0 F3: At the effective time of the Merger, each outstanding option with an exercise price equal to, or greater than, $9.12 was cancelled without any consideration payable (whether in the form of cash or any potential CVR Payments) in respect of such cancelled option. |
| Stock option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $28.14 · Expires 2028-06-19 | Direct | 0 |
Reported balance
After 2021-11-19 transaction · row 6
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 6 · 2021-11-19 · Disposition to issuer · Disposed 18,000 · Balance 0 F3: At the effective time of the Merger, each outstanding option with an exercise price equal to, or greater than, $9.12 was cancelled without any consideration payable (whether in the form of cash or any potential CVR Payments) in respect of such cancelled option. |
| Stock option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $11.74 · Expires 2029-06-18 | Direct | 0 |
Reported balance
After 2021-11-19 transaction · row 7
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 7 · 2021-11-19 · Disposition to issuer · Disposed 18,000 · Balance 0 F3: At the effective time of the Merger, each outstanding option with an exercise price equal to, or greater than, $9.12 was cancelled without any consideration payable (whether in the form of cash or any potential CVR Payments) in respect of such cancelled option. |
| Stock option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $11.88 · Expires 2030-06-09 | Direct | 0 |
Reported balance
After 2021-11-19 transaction · row 8
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 8 · 2021-11-19 · Disposition to issuer · Disposed 12,500 · Balance 0 F3: At the effective time of the Merger, each outstanding option with an exercise price equal to, or greater than, $9.12 was cancelled without any consideration payable (whether in the form of cash or any potential CVR Payments) in respect of such cancelled option. |
| Stock option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $9.22 · Expires 2031-06-23 | Direct | 0 |
Reported balance
After 2021-11-19 transaction · row 9
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 9 · 2021-11-19 · Disposition to issuer · Disposed 12,500 · Balance 0 F3: At the effective time of the Merger, each outstanding option with an exercise price equal to, or greater than, $9.12 was cancelled without any consideration payable (whether in the form of cash or any potential CVR Payments) in respect of such cancelled option. |
Filing footnotes · ownership attribution and instrument terms
F1: Pursuant to the Agreement and Plan of Merger, dated as of October 11, 2021, by and among Flexion Therapeutics, Inc. ("Issuer"), Pacira BioSciences, Inc. and Oyster Acquisition Company Inc. ("Purchaser") ("Merger Agreement"), on November 19, 2021, Purchaser merged with and into Issuer, with Issuer continuing as the surviving corporation ("Merger"). At the effective time of the Merger, each share of Issuer's common stock was cancelled in exchange for (i) $8.50 per share in cash ("Cash Amount"), plus (ii) one non-transferable contractual contingent value right per share, which represent the right to receive one or more contingent payments of up to $8.00 per share in the aggregate, in cash, upon the achievement of specified milestones on or prior to December 31, 2030 ("CVR Payments"). Pursuant to the Merger Agreement, these shares were tendered and disposed of at the offer acceptance time in exchange for the right to receive (i) the Cash Amount, plus (ii) any CVR Payments.
F2: At the effective time of the Merger, each outstanding restricted stock unit award ("RSU") was accelerated and became fully vested and was cancelled and converted into the right to receive (i) $8.50 per share of Issuer common stock issuable in settlement of such RSU in cash, net of any withholding taxes required to be deducted and withheld by applicable law, plus (ii) any potential CVR Payments.
F3: At the effective time of the Merger, each outstanding option with an exercise price equal to, or greater than, $9.12 was cancelled without any consideration payable (whether in the form of cash or any potential CVR Payments) in respect of such cancelled option.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| June 03, 2026 Filed Jun 4, 2026 20:12 UTC | Medicus Pharma Ltd. MDCX · Entity 7770 | GrantStock Option (right to buy) · Derivative | 50,000 | $0.00 Strike: $0.36 | $0.00 |
DisclosureSEC source: 0000950142-26-001638 · es260786890_4-mahaffy.xml · derivative · entry 1 MAHAFFY PATRICK J · CIK 0001266569 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 50,000 Underlying: Common Shares · 50,000 shares Expires 2031-06-03 F1 · derivative.exercise_date: The option was granted on June 3, 2026. The option is scheduled to vest quarterly in four equal installments over one year. Read SEC document |
| March 30, 2026 Filed Apr 1, 2026 23:14 UTC | Medicus Pharma Ltd. MDCX · Entity 7770 | GrantStock Option (right to buy) · Derivative | 25,000 | $0.00 Strike: $0.50 | $0.00 |
DisclosureSEC source: 0000950142-26-001028 · es260758773_4-mahaffy.xml · derivative · entry 1 MAHAFFY PATRICK J · CIK 0001266569 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 25,000 Underlying: Common Shares · 25,000 shares Expires 2031-03-27 Read SEC document |
| December 16, 2025 Filed Dec 18, 2025 21:08 UTC | Medicus Pharma Ltd. MDCX · Entity 7770 | GrantStock Option (right to buy) · Derivative | 25,000 | $0.00 Strike: $1.80 | $0.00 |
DisclosureSEC source: 0000950142-25-003236 · es250717282_4-mahaffy.xml · derivative · entry 1 MAHAFFY PATRICK J · CIK 0001266569 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 25,000 Underlying: Common Shares · 25,000 shares Expires 2030-12-16 F1 · derivative.exercise_date: The option was granted on December 16, 2025. The option is scheduled to vest quarterly in four equal installments over one year. Read SEC document |
| March 01, 2022 Filed Mar 3, 2022 16:15 UTC | Clovis Oncology, Inc. CLVS · Entity 122635 | GrantStock Option (right to buy) · Derivative | 80,000 | $0.00 Strike: $1.95 | $0.00 |
DisclosureSEC source: 0000899243-22-009061 · doc4.xml · derivative · entry 3 MAHAFFY PATRICK J · CIK 0001266569 · Director · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 80,000 Underlying: Common Stock · 80,000 shares Expires 2032-03-01 F3 · derivative.exercise_date: The option shall vest on December 31, 2022 if as of such date the Company has sufficient cash and cash equivalents or available sources of borrowings to fund the Company's operating plan, as approved by the Board as of such date, into 2024. Read SEC document |
| March 01, 2022 Filed Mar 3, 2022 16:15 UTC | Clovis Oncology, Inc. CLVS · Entity 122635 | GrantStock Option (right to buy) · Derivative | 80,000 | $0.00 Strike: $1.95 | $0.00 |
DisclosureSEC source: 0000899243-22-009061 · doc4.xml · derivative · entry 2 MAHAFFY PATRICK J · CIK 0001266569 · Director · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 80,000 Underlying: Common Stock · 80,000 shares Expires 2032-03-01 F2 · derivative.exercise_date: The option shall vest in the event Product Revenues for the Company's fiscal year ending December 31, 2022 meet or exceed its corresponding budgeted amount in the Company's budget as approved by the Board on December 2, 2021. Read SEC document |
| March 01, 2022 Filed Mar 3, 2022 16:15 UTC | Clovis Oncology, Inc. CLVS · Entity 122635 | GrantStock Option (right to buy) · Derivative | 220,000 | $0.00 Strike: $1.95 | $0.00 |
DisclosureSEC source: 0000899243-22-009061 · doc4.xml · derivative · entry 1 MAHAFFY PATRICK J · CIK 0001266569 · Director · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 220,000 Underlying: Common Stock · 220,000 shares Expires 2032-03-01 F1 · derivative.exercise_date: The option shall vest as to 25% of the shares on March 1, 2023, and the remainder shall vest in substantially equal installments over the 36 months immediately following such date. Read SEC document |
| November 19, 2021 Filed Nov 19, 2021 10:09 UTC | Flexion Therapeutics Inc FLXN · Entity 16545 | Disposition to issuerStock option (right to buy) · Derivative | 12,500 | Not disclosed Strike: $9.22 | Not disclosed |
DisclosureSEC source: 0001209191-21-065713 · doc4.xml · derivative · entry 9 MAHAFFY PATRICK J · CIK 0001266569 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 12,500 shares Expires 2031-06-23 F3 · price: At the effective time of the Merger, each outstanding option with an exercise price equal to, or greater than, $9.12 was cancelled without any consideration payable (whether in the form of cash or any potential CVR Payments) in respect of such cancelled option. F3 · derivative.exercise_date: At the effective time of the Merger, each outstanding option with an exercise price equal to, or greater than, $9.12 was cancelled without any consideration payable (whether in the form of cash or any potential CVR Payments) in respect of such cancelled option. Read SEC document |
| November 19, 2021 Filed Nov 19, 2021 10:09 UTC | Flexion Therapeutics Inc FLXN · Entity 16545 | Disposition to issuerStock option (right to buy) · Derivative | 12,500 | Not disclosed Strike: $11.88 | Not disclosed |
DisclosureSEC source: 0001209191-21-065713 · doc4.xml · derivative · entry 8 MAHAFFY PATRICK J · CIK 0001266569 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 12,500 shares Expires 2030-06-09 F3 · price: At the effective time of the Merger, each outstanding option with an exercise price equal to, or greater than, $9.12 was cancelled without any consideration payable (whether in the form of cash or any potential CVR Payments) in respect of such cancelled option. F3 · derivative.exercise_date: At the effective time of the Merger, each outstanding option with an exercise price equal to, or greater than, $9.12 was cancelled without any consideration payable (whether in the form of cash or any potential CVR Payments) in respect of such cancelled option. Read SEC document |
| November 19, 2021 Filed Nov 19, 2021 10:09 UTC | Flexion Therapeutics Inc FLXN · Entity 16545 | Disposition to issuerStock option (right to buy) · Derivative | 18,000 | Not disclosed Strike: $11.74 | Not disclosed |
DisclosureSEC source: 0001209191-21-065713 · doc4.xml · derivative · entry 7 MAHAFFY PATRICK J · CIK 0001266569 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 18,000 shares Expires 2029-06-18 F3 · price: At the effective time of the Merger, each outstanding option with an exercise price equal to, or greater than, $9.12 was cancelled without any consideration payable (whether in the form of cash or any potential CVR Payments) in respect of such cancelled option. F3 · derivative.exercise_date: At the effective time of the Merger, each outstanding option with an exercise price equal to, or greater than, $9.12 was cancelled without any consideration payable (whether in the form of cash or any potential CVR Payments) in respect of such cancelled option. Read SEC document |
| November 19, 2021 Filed Nov 19, 2021 10:09 UTC | Flexion Therapeutics Inc FLXN · Entity 16545 | Disposition to issuerStock option (right to buy) · Derivative | 18,000 | Not disclosed Strike: $28.14 | Not disclosed |
DisclosureSEC source: 0001209191-21-065713 · doc4.xml · derivative · entry 6 MAHAFFY PATRICK J · CIK 0001266569 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 18,000 shares Expires 2028-06-19 F3 · price: At the effective time of the Merger, each outstanding option with an exercise price equal to, or greater than, $9.12 was cancelled without any consideration payable (whether in the form of cash or any potential CVR Payments) in respect of such cancelled option. F3 · derivative.exercise_date: At the effective time of the Merger, each outstanding option with an exercise price equal to, or greater than, $9.12 was cancelled without any consideration payable (whether in the form of cash or any potential CVR Payments) in respect of such cancelled option. Read SEC document |
| November 19, 2021 Filed Nov 19, 2021 10:09 UTC | Flexion Therapeutics Inc FLXN · Entity 16545 | Disposition to issuerStock option (right to buy) · Derivative | 18,000 | Not disclosed Strike: $20.16 | Not disclosed |
DisclosureSEC source: 0001209191-21-065713 · doc4.xml · derivative · entry 5 MAHAFFY PATRICK J · CIK 0001266569 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 18,000 shares Expires 2027-06-21 F3 · price: At the effective time of the Merger, each outstanding option with an exercise price equal to, or greater than, $9.12 was cancelled without any consideration payable (whether in the form of cash or any potential CVR Payments) in respect of such cancelled option. F3 · derivative.exercise_date: At the effective time of the Merger, each outstanding option with an exercise price equal to, or greater than, $9.12 was cancelled without any consideration payable (whether in the form of cash or any potential CVR Payments) in respect of such cancelled option. Read SEC document |
| November 19, 2021 Filed Nov 19, 2021 10:09 UTC | Flexion Therapeutics Inc FLXN · Entity 16545 | Disposition to issuerStock option (right to buy) · Derivative | 18,000 | Not disclosed Strike: $13.83 | Not disclosed |
DisclosureSEC source: 0001209191-21-065713 · doc4.xml · derivative · entry 4 MAHAFFY PATRICK J · CIK 0001266569 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 18,000 shares Expires 2026-06-09 F3 · price: At the effective time of the Merger, each outstanding option with an exercise price equal to, or greater than, $9.12 was cancelled without any consideration payable (whether in the form of cash or any potential CVR Payments) in respect of such cancelled option. F3 · derivative.exercise_date: At the effective time of the Merger, each outstanding option with an exercise price equal to, or greater than, $9.12 was cancelled without any consideration payable (whether in the form of cash or any potential CVR Payments) in respect of such cancelled option. Read SEC document |
| November 19, 2021 Filed Nov 19, 2021 10:09 UTC | Flexion Therapeutics Inc FLXN · Entity 16545 | Disposition to issuerStock option (right to buy) · Derivative | 18,000 | Not disclosed Strike: $21.85 | Not disclosed |
DisclosureSEC source: 0001209191-21-065713 · doc4.xml · derivative · entry 3 MAHAFFY PATRICK J · CIK 0001266569 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 18,000 shares Expires 2025-06-16 F3 · price: At the effective time of the Merger, each outstanding option with an exercise price equal to, or greater than, $9.12 was cancelled without any consideration payable (whether in the form of cash or any potential CVR Payments) in respect of such cancelled option. F3 · derivative.exercise_date: At the effective time of the Merger, each outstanding option with an exercise price equal to, or greater than, $9.12 was cancelled without any consideration payable (whether in the form of cash or any potential CVR Payments) in respect of such cancelled option. Read SEC document |
| November 19, 2021 Filed Nov 19, 2021 10:09 UTC | Flexion Therapeutics Inc FLXN · Entity 16545 | Disposition to issuerStock option (right to buy) · Derivative | 18,000 | Not disclosed Strike: $17.61 | Not disclosed |
DisclosureSEC source: 0001209191-21-065713 · doc4.xml · derivative · entry 2 MAHAFFY PATRICK J · CIK 0001266569 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 18,000 shares Expires 2024-03-02 F3 · price: At the effective time of the Merger, each outstanding option with an exercise price equal to, or greater than, $9.12 was cancelled without any consideration payable (whether in the form of cash or any potential CVR Payments) in respect of such cancelled option. F3 · derivative.exercise_date: At the effective time of the Merger, each outstanding option with an exercise price equal to, or greater than, $9.12 was cancelled without any consideration payable (whether in the form of cash or any potential CVR Payments) in respect of such cancelled option. Read SEC document |
| November 19, 2021 Filed Nov 19, 2021 10:09 UTC | Flexion Therapeutics Inc FLXN · Entity 16545 | Disposition to issuerCommon Stock | 39,824 | $8.50 | $338,504.00 |
DisclosureSEC source: 0001209191-21-065713 · doc4.xml · nonDerivative · entry 1 MAHAFFY PATRICK J · CIK 0001266569 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 F1 · kind: Pursuant to the Agreement and Plan of Merger, dated as of October 11, 2021, by and among Flexion Therapeutics, Inc. ("Issuer"), Pacira BioSciences, Inc. and Oyster Acquisition Company Inc. ("Purchaser") ("Merger Agreement"), on November 19, 2021, Purchaser merged with and into Issuer, with Issuer continuing as the surviving corporation ("Merger"). At the effective time of the Merger, each share of Issuer's common stock was cancelled in exchange for (i) $8.50 per share in cash ("Cash Amount"), plus (ii) one non-transferable contractual contingent value right per share, which represent the right to receive one or more contingent payments of up to $8.00 per share in the aggregate, in cash, upon the achievement of specified milestones on or prior to December 31, 2030 ("CVR Payments"). Pursuant to the Merger Agreement, these shares were tendered and disposed of at the offer acceptance time in exchange for the right to receive (i) the Cash Amount, plus (ii) any CVR Payments. F2 · shares: At the effective time of the Merger, each outstanding restricted stock unit award ("RSU") was accelerated and became fully vested and was cancelled and converted into the right to receive (i) $8.50 per share of Issuer common stock issuable in settlement of such RSU in cash, net of any withholding taxes required to be deducted and withheld by applicable law, plus (ii) any potential CVR Payments. Read SEC document |
| June 24, 2021 Filed Jun 28, 2021 18:24 UTC | Flexion Therapeutics Inc FLXN · Entity 16545 | GrantStock option (right to buy) · Derivative | 12,500 | $0.00 Strike: $9.22 | $0.00 |
DisclosureSEC source: 0001209191-21-043539 · doc4.xml · derivative · entry 2 MAHAFFY PATRICK J · CIK 0001266569 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 12,500 Underlying: Common Stock · 12,500 shares Expires 2031-06-23 F2 · derivative.exercise_date: The stock option vests and becomes exercisable in 12 equal monthly installments following the date of grant. Read SEC document |
| June 24, 2021 Filed Jun 28, 2021 18:24 UTC | Flexion Therapeutics Inc FLXN · Entity 16545 | GrantCommon Stock | 4,500 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-21-043539 · doc4.xml · nonDerivative · entry 1 MAHAFFY PATRICK J · CIK 0001266569 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 39,824 F1 · shares: Represents a restricted stock unit award granted under the Issuer's 2013 Equity Incentive Plan. Read SEC document |
| March 01, 2021 Filed Mar 3, 2021 18:39 UTC | Clovis Oncology, Inc. CLVS · Entity 122635 | GrantStock Option (right to buy) · Derivative | 40,000 | $0.00 Strike: $6.23 | $0.00 |
DisclosureSEC source: 0000899243-21-009499 · doc4.xml · derivative · entry 4 MAHAFFY PATRICK J · CIK 0001266569 · Director · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 40,000 Underlying: Common Stock · 40,000 shares Expires 2031-03-01 F4 · derivative.exercise_date: The option shall vest upon the enrollment of three dose cohorts in the Company's LuMIERE study on or before December 31, 2021. Read SEC document |
| March 01, 2021 Filed Mar 3, 2021 18:39 UTC | Clovis Oncology, Inc. CLVS · Entity 122635 | GrantStock Option (right to buy) · Derivative | 40,000 | $0.00 Strike: $6.23 | $0.00 |
DisclosureSEC source: 0000899243-21-009499 · doc4.xml · derivative · entry 3 MAHAFFY PATRICK J · CIK 0001266569 · Director · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 40,000 Underlying: Common Stock · 40,000 shares Expires 2031-03-01 F3 · derivative.exercise_date: The option shall vest upon the selection of an alpha-emitter agent for use in the study of the Company's product candidate FAP-2286 on or before December 31, 2021. Read SEC document |
| March 01, 2021 Filed Mar 3, 2021 18:39 UTC | Clovis Oncology, Inc. CLVS · Entity 122635 | GrantStock Option (right to buy) · Derivative | 80,000 | $0.00 Strike: $6.23 | $0.00 |
DisclosureSEC source: 0000899243-21-009499 · doc4.xml · derivative · entry 2 MAHAFFY PATRICK J · CIK 0001266569 · Director · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 80,000 Underlying: Common Stock · 80,000 shares Expires 2031-03-01 F2 · derivative.exercise_date: The option shall vest in the event Product Revenues for the Company's fiscal year ending December 31, 2021 meet or exceed its corresponding budgeted amount in the Company's budget as approved by the Board on December 8, 2020. Read SEC document |
| March 01, 2021 Filed Mar 3, 2021 18:39 UTC | Clovis Oncology, Inc. CLVS · Entity 122635 | GrantStock Option (right to buy) · Derivative | 220,000 | $0.00 Strike: $6.23 | $0.00 |
DisclosureSEC source: 0000899243-21-009499 · doc4.xml · derivative · entry 1 MAHAFFY PATRICK J · CIK 0001266569 · Director · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 220,000 Underlying: Common Stock · 220,000 shares Expires 2031-03-01 F1 · derivative.exercise_date: The option shall vest as to 25% of the shares on March 1, 2022, and the remainder shall vest in substantially equal installments over the 36 months immediately following such date. Read SEC document |
| June 10, 2020 Filed Jun 12, 2020 16:24 UTC | Flexion Therapeutics Inc FLXN · Entity 16545 | GrantStock option (right to buy) · Derivative | 12,500 | $0.00 Strike: $11.88 | $0.00 |
DisclosureSEC source: 0001209191-20-036278 · doc4.xml · derivative · entry 2 MAHAFFY PATRICK J · CIK 0001266569 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 12,500 Underlying: Common Stock · 12,500 shares Expires 2030-06-09 F2 · derivative.exercise_date: The stock option vests and becomes exercisable in 12 equal monthly installments following the date of grant. Read SEC document |
| June 10, 2020 Filed Jun 12, 2020 16:24 UTC | Flexion Therapeutics Inc FLXN · Entity 16545 | GrantCommon Stock | 4,500 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-20-036278 · doc4.xml · nonDerivative · entry 1 MAHAFFY PATRICK J · CIK 0001266569 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 35,324 F1 · shares: Represents restricted stock unit award granted under the Issuer's 2013 Equity Incentive Plan. Read SEC document |
| February 13, 2020 Filed Feb 18, 2020 19:27 UTC | Clovis Oncology, Inc. CLVS · Entity 122635 | GrantStock Option (right to buy) · Derivative | 50,000 | $0.00 Strike: $9.71 | $0.00 |
DisclosureSEC source: 0000899243-20-004963 · doc4.xml · derivative · entry 1 MAHAFFY PATRICK J · CIK 0001266569 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 50,000 Underlying: Common Stock · 50,000 shares Expires 2030-02-13 F1 · derivative.exercise_date: The option shall vest in the event the Company's Product Revenues for the Company's fiscal year ending December 31, 2020 meet or exceed its corresponding budgeted amount in the Company's budget as approved by the Board of Directors on February 13, 2020. Read SEC document |
| February 03, 2020 Filed Feb 3, 2020 17:05 UTC | Clovis Oncology, Inc. CLVS · Entity 122635 | GrantStock Option (right to buy) · Derivative | 50,000 | $0.00 Strike: $8.39 | $0.00 |
DisclosureSEC source: 0000899243-20-002563 · doc4.xml · derivative · entry 2 MAHAFFY PATRICK J · CIK 0001266569 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 50,000 Underlying: Common Stock · 50,000 shares Expires 2030-02-03 F2 · derivative.exercise_date: The option shall vest upon the submission by the Company to the FDA of an IND for FAP-2286 on or before December 31, 2020. Read SEC document |
| February 03, 2020 Filed Feb 3, 2020 17:05 UTC | Clovis Oncology, Inc. CLVS · Entity 122635 | GrantStock Option (right to buy) · Derivative | 200,000 | $0.00 Strike: $8.39 | $0.00 |
DisclosureSEC source: 0000899243-20-002563 · doc4.xml · derivative · entry 1 MAHAFFY PATRICK J · CIK 0001266569 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 200,000 Underlying: Common Stock · 200,000 shares Expires 2030-02-03 F1 · derivative.exercise_date: The option shall vest as to 25% of the shares on January 31, 2021, and the remainder shall vest in substantially equal installments over the 36 months immediately following such date. Read SEC document |
| August 29, 2019 Filed Aug 29, 2019 16:46 UTC | Flexion Therapeutics Inc FLXN · Entity 16545 | Exercise / conversionStock Option (right to buy) · Derivative | 30,824 | $0.00 Strike: $0.16 | $0.00 |
DisclosureSEC source: 0001209191-19-047709 · doc4.xml · derivative · entry 2 MAHAFFY PATRICK J · CIK 0001266569 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 30,824 shares Expires 2019-09-23 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_date: The stock option is fully vested and exercisable. Read SEC document |
| August 29, 2019 Filed Aug 29, 2019 16:46 UTC | Flexion Therapeutics Inc FLXN · Entity 16545 | Exercise / conversionCommon Stock | 30,824 | $0.16 | $4,931.84 |
DisclosureSEC source: 0001209191-19-047709 · doc4.xml · nonDerivative · entry 1 MAHAFFY PATRICK J · CIK 0001266569 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 30,824 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| August 16, 2019 Filed Aug 19, 2019 08:35 UTC | Clovis Oncology, Inc. CLVS · Entity 122635 | PurchaseCommon Stock | 5,827 | $5.60 | $32,631.20 |
DisclosureSEC source: 0000899243-19-022005 · doc4.xml · nonDerivative · entry 10 MAHAFFY PATRICK J · CIK 0001266569 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 968,787 Read SEC document |
| August 16, 2019 Filed Aug 19, 2019 08:35 UTC | Clovis Oncology, Inc. CLVS · Entity 122635 | PurchaseCommon Stock | 5,100 | $5.60 | $28,560.00 |
DisclosureSEC source: 0000899243-19-022005 · doc4.xml · nonDerivative · entry 9 MAHAFFY PATRICK J · CIK 0001266569 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 962,960 Read SEC document |
| August 16, 2019 Filed Aug 19, 2019 08:35 UTC | Clovis Oncology, Inc. CLVS · Entity 122635 | PurchaseCommon Stock | 11,053 | $5.59 | $61,786.27 |
DisclosureSEC source: 0000899243-19-022005 · doc4.xml · nonDerivative · entry 8 MAHAFFY PATRICK J · CIK 0001266569 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 957,860 Read SEC document |
| August 16, 2019 Filed Aug 19, 2019 08:35 UTC | Clovis Oncology, Inc. CLVS · Entity 122635 | PurchaseCommon Stock | 3,700 | $5.59 | $20,683.00 |
DisclosureSEC source: 0000899243-19-022005 · doc4.xml · nonDerivative · entry 7 MAHAFFY PATRICK J · CIK 0001266569 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 946,807 Read SEC document |
| August 16, 2019 Filed Aug 19, 2019 08:35 UTC | Clovis Oncology, Inc. CLVS · Entity 122635 | PurchaseCommon Stock | 11,314 | $5.58 | $63,132.12 |
DisclosureSEC source: 0000899243-19-022005 · doc4.xml · nonDerivative · entry 6 MAHAFFY PATRICK J · CIK 0001266569 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 943,107 Read SEC document |
| August 16, 2019 Filed Aug 19, 2019 08:35 UTC | Clovis Oncology, Inc. CLVS · Entity 122635 | PurchaseCommon Stock | 6,400 | $5.61 | $35,904.00 |
DisclosureSEC source: 0000899243-19-022005 · doc4.xml · nonDerivative · entry 5 MAHAFFY PATRICK J · CIK 0001266569 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 931,793 Read SEC document |
| August 16, 2019 Filed Aug 19, 2019 08:35 UTC | Clovis Oncology, Inc. CLVS · Entity 122635 | PurchaseCommon Stock | 2,100 | $5.61 | $11,781.00 |
DisclosureSEC source: 0000899243-19-022005 · doc4.xml · nonDerivative · entry 4 MAHAFFY PATRICK J · CIK 0001266569 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 925,393 Read SEC document |
| August 16, 2019 Filed Aug 19, 2019 08:35 UTC | Clovis Oncology, Inc. CLVS · Entity 122635 | PurchaseCommon Stock | 3,706 | $5.57 | $20,642.42 |
DisclosureSEC source: 0000899243-19-022005 · doc4.xml · nonDerivative · entry 3 MAHAFFY PATRICK J · CIK 0001266569 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 923,293 Read SEC document |
| August 16, 2019 Filed Aug 19, 2019 08:35 UTC | Clovis Oncology, Inc. CLVS · Entity 122635 | PurchaseCommon Stock | 400 | $5.58 | $2,232.00 |
DisclosureSEC source: 0000899243-19-022005 · doc4.xml · nonDerivative · entry 2 MAHAFFY PATRICK J · CIK 0001266569 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 919,587 Read SEC document |
| August 16, 2019 Filed Aug 19, 2019 08:35 UTC | Clovis Oncology, Inc. CLVS · Entity 122635 | PurchaseCommon Stock | 400 | $5.56 | $2,224.00 |
DisclosureSEC source: 0000899243-19-022005 · doc4.xml · nonDerivative · entry 1 MAHAFFY PATRICK J · CIK 0001266569 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 919,187 Read SEC document |
| June 19, 2019 Filed Jun 21, 2019 16:02 UTC | Flexion Therapeutics Inc FLXN · Entity 16545 | GrantStock option (right to buy) · Derivative | 18,000 | $0.00 Strike: $11.74 | $0.00 |
DisclosureSEC source: 0001209191-19-038447 · doc4.xml · derivative · entry 1 MAHAFFY PATRICK J · CIK 0001266569 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 18,000 Underlying: Common Stock · 18,000 shares Expires 2029-06-18 F1 · derivative.exercise_date: The stock option vests and becomes exercisable in 12 equal monthly installments following the date of grant. Read SEC document |
| February 01, 2019 Filed Feb 4, 2019 18:01 UTC | Clovis Oncology, Inc. CLVS · Entity 122635 | GrantStock Option (right to buy) · Derivative | 100,000 | $0.00 Strike: $25.75 | $0.00 |
DisclosureSEC source: 0000899243-19-002504 · doc4.xml · derivative · entry 2 MAHAFFY PATRICK J · CIK 0001266569 · Director · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 100,000 Underlying: Common Stock · 100,000 shares Expires 2029-02-01 F2 · derivative.exercise_date: The option shall vest in the event the Company's Product Revenues for the Company's fiscal year ending December 31, 2019 meet or exceed its corresponding budgeted amount in the Company's budget as approved by the Board of Directors on December 6, 2018. Read SEC document |
| February 01, 2019 Filed Feb 4, 2019 18:01 UTC | Clovis Oncology, Inc. CLVS · Entity 122635 | GrantStock Option (right to buy) · Derivative | 200,000 | $0.00 Strike: $25.75 | $0.00 |
DisclosureSEC source: 0000899243-19-002504 · doc4.xml · derivative · entry 1 MAHAFFY PATRICK J · CIK 0001266569 · Director · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 200,000 Underlying: Common Stock · 200,000 shares Expires 2029-02-01 F1 · derivative.exercise_date: The option shall vest as to 25% of the shares on February 1, 2020, and the remainder shall vest in substantially equal installments over the 36 months immediately following such date. Read SEC document |
| June 20, 2018 Filed Jun 21, 2018 16:08 UTC | Flexion Therapeutics Inc FLXN · Entity 16545 | GrantStock option (right to buy) · Derivative | 18,000 | $0.00 Strike: $28.14 | $0.00 |
DisclosureSEC source: 0001209191-18-038928 · doc4.xml · derivative · entry 1 MAHAFFY PATRICK J · CIK 0001266569 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 18,000 Underlying: Common Stock · 18,000 shares Expires 2028-06-19 F1 · derivative.exercise_date: The stock option vests and becomes exercisable in 12 equal monthly installments following the date of grant. Read SEC document |
| March 01, 2018 Filed Mar 2, 2018 18:25 UTC | Clovis Oncology, Inc. CLVS · Entity 122635 | GrantStock Option (right to buy) · Derivative | 120,000 | $0.00 Strike: $58.43 | $0.00 |
DisclosureSEC source: 0000899243-18-006219 · doc4.xml · derivative · entry 1 MAHAFFY PATRICK J · CIK 0001266569 · Director · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 120,000 Underlying: Common Stock · 120,000 shares Expires 2028-03-01 F1 · derivative.exercise_date: The option shall vest as to 25% of the shares on March 1, 2019, and the remainder shall vest in substantially equal installments over the 36 months immediately following such date. Read SEC document |
| July 14, 2017 Filed Jul 18, 2017 23:46 UTC | Orexigen Therapeutics, Inc. OREX · Entity 157016 | GrantStock Option (Right to Buy) · Derivative | 5,000 | $0.00 Strike: $2.88 | $0.00 |
DisclosureSEC source: 0001209191-17-045603 · doc4.xml · derivative · entry 1 MAHAFFY PATRICK J · CIK 0001266569 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,000 Underlying: Common Stock · 5,000 shares Expires 2027-07-13 F1 · derivative.exercise_date: 1/12th of the original number of shares of stock subject to the option (rounded down to the next whole number of shares) shall vest in equal monthly installments over 12 months following the vesting commencement date of July 14, 2017, subject to the Reporting Person's continuing service on the Issuer's Board of Directors through each such date, and subject to the terms of the Stock Option Agreement in the event of a change in control of the Issuer. Read SEC document |
| June 22, 2017 Filed Jul 27, 2017 09:34 UTC | Flexion Therapeutics Inc FLXN · Entity 16545 | GrantStock Option (Right to Buy) · Derivative | 18,000 | $0.00 Strike: $20.16 | $0.00 |
DisclosureSEC source: 0001209191-17-046387 · doc4.xml · derivative · entry 1 MAHAFFY PATRICK J · CIK 0001266569 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 18,000 Underlying: Common Stock · 18,000 shares Expires 2027-06-21 F1 · derivative.exercise_date: The stock option vests and becomes exercisable in 12 equal monthly installments following the date of grant. Read SEC document |
| March 27, 2017 Filed Mar 28, 2017 18:49 UTC | Clovis Oncology, Inc. CLVS · Entity 122635 | GrantStock Option (right to buy) · Derivative | 150,000 | $0.00 Strike: $68.31 | $0.00 |
DisclosureSEC source: 0000899243-17-008769 · doc4.xml · derivative · entry 1 MAHAFFY PATRICK J · CIK 0001266569 · Director · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 150,000 Underlying: Common Stock · 150,000 shares Expires 2027-03-27 F1 · derivative.exercise_date: The option shall vest as to 12.5% of the shares on March 1, 2018, and as to 37.5% of the shares in substantially equal installments over the 36 months immediately following such date. The option shall vest as to 50% of the shares upon the approval by the U.S. Food & Drug Administration of a supplemental NDA for second-line maintenance therapy for Rubraca based on data from the ARIEL3 trial. Read SEC document |
| September 16, 2016 Filed Sep 19, 2016 18:12 UTC | Clovis Oncology, Inc. CLVS · Entity 122635 | OtherStock Option (right to buy) · Derivative | 25,000 | $0.00 Strike: $79.05 | $0.00 |
DisclosureSEC source: 0000899243-16-029283 · doc4.xml · derivative · entry 1 MAHAFFY PATRICK J · CIK 0001266569 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 75,000 Underlying: Common Stock · 25,000 shares Expires 2025-03-02 F1 · derivative.exercise_date: The Reporting Person voluntarily forfeited the option as to 25,000 of the shares, which was subject to vesting upon the approval by the U.S. Food and Drug Administration to commercially distribute, sell or market Rociletinib. Following such forfeiture, the Reporting Person holds the option as to the remaining 75,000 shares (the "Remaining Shares"). The option vested as to 12,500 of such Remaining Shares on March 2, 2016 and has vested or will vest as to 37,500 of such Remaining Shares in substantially equal installments over the 12 quarters immediately following such date. The option shall vest as to 25,000 of such Remaining Shares upon the approval by the U.S. Food and Drug Administration to commercially distribute, sell or market Rucaparib. F1 · balance_after: The Reporting Person voluntarily forfeited the option as to 25,000 of the shares, which was subject to vesting upon the approval by the U.S. Food and Drug Administration to commercially distribute, sell or market Rociletinib. Following such forfeiture, the Reporting Person holds the option as to the remaining 75,000 shares (the "Remaining Shares"). The option vested as to 12,500 of such Remaining Shares on March 2, 2016 and has vested or will vest as to 37,500 of such Remaining Shares in substantially equal installments over the 12 quarters immediately following such date. The option shall vest as to 25,000 of such Remaining Shares upon the approval by the U.S. Food and Drug Administration to commercially distribute, sell or market Rucaparib. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.